Pamela J. McLean, Ph.D. - Publications

Affiliations: 
Neuroscience Mayo Clinic Florida 
Area:
Parkinson's disease, alpha-synuclein

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Agarwal K, Backler W, Bayram E, Bloom L, Boeve BF, Cha JH, Denslow M, Ferman TJ, Galasko D, Galvin JE, Gomperts SN, Irizarry MC, Kantarci K, Kaushik H, Kietlinski M, ... ... McLean PJ, et al. Lewy body dementia: Overcoming barriers and identifying solutions. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38265159 DOI: 10.1002/alz.13674  0.459
2023 Burgess JD, Amerna D, Norton ES, Parsons TM, Perkerson RB, Faroqi AH, Wszolek ZK, Guerrero Cazares H, Kanekiyo T, Delenclos M, McLean PJ. A mutant methionyl-tRNA synthetase-based toolkit to assess induced-mesenchymal stromal cell secretome in mixed-culture disease models. Stem Cell Research & Therapy. 14: 289. PMID 37798772 DOI: 10.1186/s13287-023-03515-0  0.712
2023 Basu S, Song M, Adams L, Jeong I, Je G, Guhathakurta S, Jiang J, Boparai N, Dai W, Cardozo-Pelaez F, Tatulian SA, Han KY, Elliott J, Baum J, McLean PJ, et al. Transcriptional mutagenesis of α-synuclein caused by DNA oxidation in Parkinson's disease pathogenesis. Acta Neuropathologica. PMID 37740734 DOI: 10.1007/s00401-023-02632-7  0.35
2023 Fagen SJ, Burgess JD, Lim MJ, Amerna D, Kaya ZB, Faroqi AH, Perisetla P, DeMeo NN, Stojkovska I, Quiriconi DJ, Mazzulli JR, Delenclos M, Boschen SL, McLean PJ. Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression. Frontiers in Aging Neuroscience. 15: 1179086. PMID 37637959 DOI: 10.3389/fnagi.2023.1179086  0.837
2023 Kaya ZB, Karakoc E, McLean PJ, Saka E, Atilla P. Post-inflammatory administration of -acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson's disease. Faseb Bioadvances. 5: 263-276. PMID 37415931 DOI: 10.1096/fba.2022-00145  0.358
2023 Hou X, Chen TH, Koga S, Bredenberg JM, Faroqi AH, Delenclos M, Bu G, Wszolek ZK, Carr JA, Ross OA, McLean PJ, Murray ME, Dickson DW, Fiesel FC, Springer W. Alpha-synuclein-associated changes in PINK1-PRKN-mediated mitophagy are disease context dependent. Brain Pathology (Zurich, Switzerland). e13175. PMID 37259617 DOI: 10.1111/bpa.13175  0.414
2023 Burgess JD, Amerna D, Norton ES, Parsons TM, Iii RBP, Faroqi AH, Wszolek ZK, Cazares HG, Kanekiyo T, Delenclos M, McLean PJ. A Mutant Methionyl-tRNA Synthetase-Based toolkit to assess induced-Mesenchymal Stromal Cell secretome in mixed-culture disease models. Research Square. PMID 37205579 DOI: 10.21203/rs.3.rs-2838195/v1  0.712
2022 Kolicheski A, Turcano P, Tamvaka N, McLean PJ, Springer W, Savica R, Ross OA. Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder. Journal of Parkinson's Disease. 12: 2353-2367. PMID 36502340 DOI: 10.3233/JPD-223380  0.328
2022 Milanowski LM, Hou X, Bredenberg JM, Fiesel FC, Cocker LT, Soto-Beasley AI, Walton RL, Strongosky AJ, Faroqi AH, Barcikowska M, Boczarska-Jedynak M, Dulski J, Fedoryshyn L, Janik P, Potulska-Chromik A, ... ... McLean PJ, et al. Cathepsin B p.Gly284Val Variant in Parkinson's Disease Pathogenesis. International Journal of Molecular Sciences. 23. PMID 35806091 DOI: 10.3390/ijms23137086  0.796
2022 Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, Heckman MG, Ikezu TC, Li Z, Burgess JD, Amerna D, O'Leary J, DeTure MA, Zhao J, McLean PJ, et al. APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology. Acta Neuropathologica. PMID 35471463 DOI: 10.1007/s00401-022-02421-8  0.743
2022 Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Molecular Neurodegeneration. 17: 16. PMID 35197079 DOI: 10.1186/s13024-022-00520-4  0.637
2020 Faroqi AH, Lim MJ, Kee EC, Lee JH, Burgess JD, Chen R, Di Virgilio F, Delenclos M, McLean PJ. In vivo detection of extracellular ATP in a mouse model of traumatic brain injury. Journal of Neurotrauma. PMID 32935624 DOI: 10.1089/Neu.2020.7226  0.756
2020 Soto-Beasley AI, Walton RL, Valentino RR, Hook PW, Labbé C, Heckman MG, Johnson PW, Goff LA, Uitti RJ, McLean PJ, Springer W, McCallion AS, Wszolek ZK, Ross OA. Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease. Parkinsonism & Related Disorders. 78: 138-144. PMID 32829096 DOI: 10.1016/J.Parkreldis.2020.07.022  0.37
2020 Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J, Van Ingelgom AJ, Davis MD, Kurti A, Knight JA, Linares C, ... ... McLean PJ, et al. APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid. Science Translational Medicine. 12. PMID 32024798 DOI: 10.1126/Scitranslmed.Aay1809  0.433
2020 Park JH, Burgess JD, Faroqi AH, DeMeo NN, Fiesel FC, Springer W, Delenclos M, McLean PJ. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Molecular Neurodegeneration. 15: 5. PMID 31931835 DOI: 10.1186/S13024-019-0349-X  0.786
2019 Kiechle M, von Einem B, Höfs L, Voehringer P, Grozdanov V, Markx D, Parlato R, Wiesner D, Mayer B, Sakk O, Baumann B, Lukassen S, Liss B, Ekici AB, Ludolph AC, ... ... McLean PJ, et al. In Vivo Protein Complementation Demonstrates Presynaptic α-Synuclein Oligomerization and Age-Dependent Accumulation of 8-16-mer Oligomer Species. Cell Reports. 29: 2862-2874.e9. PMID 31775051 DOI: 10.1016/J.Celrep.2019.10.089  0.711
2019 Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM. Increased immune activation by pathologic alpha-synuclein in Parkinson's Disease. Annals of Neurology. PMID 31343083 DOI: 10.1002/Ana.25557  0.735
2019 Delenclos M, Burgess JD, Lamprokostopoulou A, Outeiro TF, Vekrellis K, McLean PJ. Cellular models of alpha-synuclein toxicity and aggregation. Journal of Neurochemistry. PMID 31265132 DOI: 10.1111/Jnc.14806  0.801
2019 Sun J, Carlson-Stevermer J, Das U, Shen M, Delenclos M, Snead AM, Koo SY, Wang L, Qiao D, Loi J, Petersen AJ, Stockton M, Bhattacharyya A, Jones MV, Zhao X, ... McLean PJ, et al. CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage. Nature Communications. 10: 53. PMID 30604771 DOI: 10.1038/S41467-018-07971-8  0.381
2018 Wang B, Underwood R, Kamath A, Britain C, McFerrin MB, McLean PJ, Volpicelli-Daley LA, Whitaker RH, Placzek WJ, Becker K, Ma J, Yacoubian TA. 14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 30093536 DOI: 10.1523/Jneurosci.1134-18.2018  0.57
2018 Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. Ebiomedicine. PMID 29433982 DOI: 10.1016/J.Ebiom.2018.01.035  0.668
2017 Jiang P, Gan M, Yen SH, McLean PJ, Dickson DW. Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α-synuclein aggregates. Scientific Reports. 7: 7690. PMID 28794446 DOI: 10.1038/S41598-017-08149-W  0.774
2017 von Einem B, Eschbach J, Kiechle M, Wahler A, Thal DR, McLean PJ, Weishaupt JH, Ludolph AC, von Arnim CAF, Danzer KM. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion. Aging. PMID 28722658 DOI: 10.18632/aging.101261  0.712
2017 Delenclos M, Faroqi AH, Yue M, Kurti A, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Fryer JD, McLean PJ. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathologica Communications. 5: 51. PMID 28645308 DOI: 10.1186/S40478-017-0455-3  0.812
2017 McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, ... ... McLean P, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. PMID 28592453 DOI: 10.1212/Wnl.0000000000004058  0.32
2017 Delenclos M, Trendafilova T, Mahesh D, Baine AM, Moussaud S, Yan IK, Patel T, McLean PJ. Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Frontiers in Neuroscience. 11: 172. PMID 28424577 DOI: 10.3389/Fnins.2017.00172  0.821
2016 Jiang P, Gan M, Yen SH, McLean PJ, Dickson DW. Histones facilitate α-synuclein aggregation during neuronal apoptosis. Acta Neuropathologica. PMID 28004278 DOI: 10.1007/S00401-016-1660-Z  0.778
2016 Helferich AM, McLean PJ, Weishaupt JH, Danzer KM. Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. Journal of Neurology & Neuromedicine. 1: 28-30. PMID 27853754  0.724
2016 Jarvela TS, Lam HA, Helwig M, Lorenzen N, Otzen DE, McLean PJ, Maidment NT, Lindberg I. The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America. PMID 27457957 DOI: 10.1073/Pnas.1601091113  0.518
2016 Levin J, Hillmer AS, Högen T, McLean PJ, Giese A. Intracellular formation of α-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochemical and Biophysical Research Communications. PMID 27286709 DOI: 10.1016/J.Bbrc.2016.06.023  0.456
2016 Jiang P, Gan M, Yen SH, Moussaud S, McLean PJ, Dickson DW. Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons. Acta Neuropathologica. PMID 26839082 DOI: 10.1007/S00401-016-1542-4  0.835
2015 Delenclos M, Trendafilova T, Jones DR, Moussaud S, Baine AM, Yue M, Hirst WD, McLean PJ. A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. Frontiers in Neuroscience. 9: 511. PMID 26834539 DOI: 10.3389/Fnins.2015.00511  0.836
2015 Helferich AM, Ruf WP, Grozdanov V, Freischmidt A, Feiler MS, Zondler L, Ludolph AC, McLean PJ, Weishaupt JH, Danzer KM. α-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration. 10: 66. PMID 26643113 DOI: 10.1186/S13024-015-0062-3  0.713
2015 Jones DR, Delenclos M, Baine AT, DeTure M, Murray ME, Dickson DW, McLean PJ. Transmission of Soluble and Insoluble α-Synuclein to Mice. Journal of Neuropathology and Experimental Neurology. 74: 1158-1169. PMID 26574670 DOI: 10.1097/Nen.0000000000000262  0.663
2015 Delenclos M, Moussaud S, McLean PJ. Untangling a Role for Tau in Synucleinopathies. Biological Psychiatry. 78: 666-7. PMID 26497280 DOI: 10.1016/J.Biopsych.2015.08.020  0.764
2015 Lindberg I, Shorter J, Wiseman RL, Chiti F, Dickey CA, McLean PJ. Chaperones in Neurodegeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 13853-9. PMID 26468185 DOI: 10.1523/Jneurosci.2600-15.2015  0.384
2015 Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism & Related Disorders. PMID 26439946 DOI: 10.1016/J.Parkreldis.2015.09.048  0.601
2015 Lorenzo-Betancor O, Ogaki K, Soto-Ortolaza AI, Labbe C, Walton RL, Strongosky AJ, van Gerpen JA, Uitti RJ, McLean PJ, Springer W, Siuda J, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, et al. DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 1323-5. PMID 26278106 DOI: 10.1111/Ene.12770  0.401
2015 Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiology of Disease. 78: 172-95. PMID 25836420 DOI: 10.1016/J.Nbd.2015.02.031  0.351
2015 Moussaud S, Malany S, Mehta A, Vasile S, Smith LH, McLean PJ. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opinion On Therapeutic Targets. 19: 589-603. PMID 25785645 DOI: 10.1517/14728222.2015.1009448  0.796
2015 Gan M, Moussaud S, Jiang P, McLean PJ. Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiology of Aging. 36: 1209-20. PMID 25480524 DOI: 10.1016/J.Neurobiolaging.2014.10.037  0.828
2015 Eschbach J, von Einem B, Müller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, et al. Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Annals of Neurology. 77: 15-32. PMID 25363075 DOI: 10.1002/Ana.24294  0.697
2014 Gan M, Jiang P, McLean P, Kanekiyo T, Bu G. Low-density lipoprotein receptor-related protein 1 (LRP1) regulates the stability and function of GluA1 α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor in neurons. Plos One. 9: e113237. PMID 25500815 DOI: 10.1371/Journal.Pone.0113237  0.719
2014 Moussaud S, Jones DR, Moussaud-Lamodière EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Molecular Neurodegeneration. 9: 43. PMID 25352339 DOI: 10.1186/1750-1326-9-43  0.83
2014 Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S. α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Current Biology : Cb. 24: 2319-26. PMID 25264250 DOI: 10.1016/J.Cub.2014.08.027  0.331
2014 Winslow AR, Moussaud S, Zhu L, Post KL, Post KL, Dickson DW, Berezovska O, McLean PJ. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain : a Journal of Neurology. 137: 1958-70. PMID 24860142 DOI: 10.1093/Brain/Awu119  0.818
2014 Dimant H, Zhu L, Kibuuka LN, Fan Z, Hyman BT, McLean PJ. Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. Plos One. 9: e92098. PMID 24664141 DOI: 10.1371/Journal.Pone.0092098  0.857
2014 McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048. PMID 24465863 DOI: 10.1371/Journal.Pone.0086048  0.795
2014 Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate α-synuclein toxicity. Therapeutic Advances in Neurological Disorders. 7: 33-51. PMID 24409201 DOI: 10.1177/1756285613493469  0.818
2013 Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications. 1: 6. PMID 24252244 DOI: 10.1186/2051-5960-1-6  0.831
2013 Neal KL, Shakerdge NB, Hou SS, Klunk WE, Mathis CA, Nesterov EE, Swager TM, McLean PJ, Bacskai BJ. Development and screening of contrast agents for in vivo imaging of Parkinson's disease. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 15: 585-95. PMID 23624948 DOI: 10.1007/s11307-013-0634-y  0.391
2013 Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology. 73: 155-69. PMID 23225525 DOI: 10.1002/Ana.23746  0.732
2013 Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Constructs used in this study and complementation results. Plos One. DOI: 10.1371/Journal.Pone.0001867.T001  0.749
2012 Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, ... ... McLean PJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8: 445-544. PMID 22966490 DOI: 10.4161/Auto.19496  0.666
2012 Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration. 7: 42. PMID 22920859 DOI: 10.1186/1750-1326-7-42  0.849
2012 Dimant H, Ebrahimi-Fakhari D, McLean PJ. Molecular chaperones and co-chaperones in Parkinson disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 18: 589-601. PMID 22829394 DOI: 10.1177/1073858412441372  0.836
2012 Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathologica. 124: 153-72. PMID 22744791 DOI: 10.1007/S00401-012-1004-6  0.477
2012 Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, Schlötzer-Schrehardt U, Hyman BT, McLean PJ, Masliah E, Winkler J. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy. 8: 754-66. PMID 22647715 DOI: 10.4161/Auto.19371  0.682
2012 Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy. 8: 281-3. PMID 22301995 DOI: 10.4161/Auto.8.2.18938  0.783
2012 Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 124-32. PMID 22219275 DOI: 10.1523/Jneurosci.3442-11.2012  0.453
2011 Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Molecular chaperones in Parkinson's disease--present and future. Journal of Parkinson's Disease. 1: 299-320. PMID 22279517 DOI: 10.3233/Jpd-2011-11044  0.467
2011 Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 14508-20. PMID 21994367 DOI: 10.1523/Jneurosci.1560-11.2011  0.799
2011 Danzer KM, McLean PJ. Drug targets from genetics: α-synuclein. Cns & Neurological Disorders Drug Targets. 10: 712-23. PMID 21838671 DOI: 10.2174/187152711797247867  0.723
2011 Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 146: 37-52. PMID 21700325 DOI: 10.1016/J.Cell.2011.06.001  0.51
2011 Hashimoto T, Adams KW, Fan Z, McLean PJ, Hyman BT. Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. The Journal of Biological Chemistry. 286: 27081-91. PMID 21652708 DOI: 10.1074/Jbc.M111.257378  0.718
2011 Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). Plos One. 6: e14695. PMID 21358815 DOI: 10.1371/Journal.Pone.0014695  0.783
2011 Unni VK, Ebrahimi-Fakhari D, Vanderburg CR, McLean PJ, Hyman BT. Studying protein degradation pathways in vivo using a cranial window-based approach. Methods (San Diego, Calif.). 53: 194-200. PMID 21187150 DOI: 10.1016/J.Ymeth.2010.12.032  0.773
2011 Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 25: 326-36. PMID 20876215 DOI: 10.1096/Fj.10-164624  0.824
2010 Kalia SK, Kalia LV, McLean PJ. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. Cns & Neurological Disorders Drug Targets. 9: 741-53. PMID 20942788 DOI: 10.2174/187152710793237386  0.485
2010 Unni VK, Weissman TA, Rockenstein E, Masliah E, McLean PJ, Hyman BT. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. Plos One. 5: e10589. PMID 20485674 DOI: 10.1371/Journal.Pone.0010589  0.815
2010 Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. The Journal of Pharmacology and Experimental Therapeutics. 332: 849-57. PMID 19934398 DOI: 10.1124/Jpet.109.158436  0.831
2010 Hillmer AS, Putcha P, Levin J, Högen T, Hyman BT, Kretzschmar H, McLean PJ, Giese A. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochemical and Biophysical Research Communications. 391: 461-6. PMID 19914207 DOI: 10.1016/J.Bbrc.2009.11.080  0.838
2009 Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. The Journal of Clinical Investigation. 119: 3257-65. PMID 19855133 DOI: 10.1172/Jci39088  0.68
2009 Outeiro TF, Klucken J, Bercury K, Tetzlaff J, Putcha P, Oliveira LM, Quintas A, McLean PJ, Hyman BT. Dopamine-induced conformational changes in alpha-synuclein. Plos One. 4: e6906. PMID 19730729 DOI: 10.1371/Journal.Pone.0006906  0.824
2009 McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 68: 515-24. PMID 19525899 DOI: 10.1097/Nen.0B013E3181A24B53  0.833
2009 McFarland NR, Lee JS, Hyman BT, McLean PJ. Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. Journal of Neurochemistry. 109: 838-45. PMID 19250335 DOI: 10.1111/J.1471-4159.2009.06010.X  0.806
2009 Spiegel ET, Jones P, McLean P, Hyman B, Zipfel WR. Probing the effect of Heat Shock Protein 70 on the aggregation of α-Synuclein Biophysical Journal. 96: 92a. DOI: 10.1016/J.Bpj.2008.12.381  0.437
2008 Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 67: 1149-58. PMID 19018246 DOI: 10.1097/Nen.0B013E31818E5E99  0.471
2008 Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology. 213: 315-25. PMID 18625222 DOI: 10.1016/J.Expneurol.2008.06.004  0.49
2008 Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, McLean PJ. CHIP targets toxic alpha-Synuclein oligomers for degradation. The Journal of Biological Chemistry. 283: 17962-8. PMID 18436529 DOI: 10.1074/Jbc.M802283200  0.817
2008 Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Formation of toxic oligomeric alpha-synuclein species in living cells. Plos One. 3: e1867. PMID 18382657 DOI: 10.1371/Journal.Pone.0001867  0.837
2008 Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, McLean PJ, Hyman BT, Standaert DG. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease. 29: 515-28. PMID 18191405 DOI: 10.1016/J.Nbd.2007.11.008  0.637
2008 Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells Plos One. 3. DOI: 10.1371/Annotation/9282F173-Df82-4B70-9120-B4E62B3Dacb1  0.785
2007 Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (New York, N.Y.). 317: 516-9. PMID 17588900 DOI: 10.1126/Science.1143780  0.688
2007 St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry. 100: 1449-57. PMID 17241127 DOI: 10.1111/J.1471-4159.2006.04310.X  0.7
2007 Klucken J, McLean P, Hyman B, Bogdahn U, Winkler J. Chaperon Proteine steuern die alpha-Synuclein Aggregation und Degradation Aktuelle Neurologie. 34. DOI: 10.1055/S-2007-987900  0.627
2007 Outeiro TF, McLean PJ, Hyman BT. Protein aggregation disorders Neurobiology of Disease. 111-123. DOI: 10.1016/B978-012088592-3/50012-8  0.662
2006 Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochemical and Biophysical Research Communications. 351: 631-8. PMID 17081499 DOI: 10.1016/J.Bbrc.2006.10.085  0.677
2006 Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2050-7. PMID 17012257 DOI: 10.1096/Fj.05-5422Com  0.678
2006 Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proceedings of the National Academy of Sciences of the United States of America. 103: 4246-51. PMID 16537516 DOI: 10.1073/Pnas.0511256103  0.661
2006 Giaime E, Sunyach C, Herrant M, Grosso S, Auberger P, McLean PJ, Checler F, da Costa CA. Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway. The Journal of Biological Chemistry. 281: 11515-22. PMID 16495229 DOI: 10.1074/Jbc.M508619200  0.39
2006 Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathologica. 111: 101-8. PMID 16482476 DOI: 10.1007/S00401-005-0027-7  0.748
2005 Cantuti-Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, McLean PJ, Frosch MP, Hyman BT, Standaert DG. Alpha-synuclein and chaperones in dementia with Lewy bodies. Journal of Neuropathology and Experimental Neurology. 64: 1058-66. PMID 16319716 DOI: 10.1097/01.Jnen.0000190063.90440.69  0.619
2005 Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 7278-87. PMID 16079410 DOI: 10.1523/Jneurosci.1879-05.2005  0.573
2005 Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. The Journal of Biological Chemistry. 280: 23727-34. PMID 15845543 DOI: 10.1074/Jbc.M503326200  0.689
2004 Klucken J, Shin Y, Hyman BT, McLean PJ. A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochemical and Biophysical Research Communications. 325: 367-73. PMID 15522241 DOI: 10.1016/J.Bbrc.2004.10.037  0.687
2004 McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochemical and Biophysical Research Communications. 321: 665-9. PMID 15358157 DOI: 10.1016/J.Bbrc.2004.07.021  0.673
2004 Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. The Journal of Biological Chemistry. 279: 25497-502. PMID 15044495 DOI: 10.1074/Jbc.M400255200  0.69
2004 Klucken J, Shin Y, Mclean P, Hyman B. Chaperone mediated degradation of aggregated alpha synuclein Aktuelle Neurologie. 31. DOI: 10.1055/S-2004-833268  0.63
2004 Shin Y, McLean PJ, Hyman BT. P3-268 Chip colocalizes with phosphorylated tau in neurofibrillary tangles in AD brain Neurobiology of Aging. 25: S431. DOI: 10.1016/S0197-4580(04)81418-0  0.525
2004 McLean PJ, Klucken J, Shin Y, Hyman BT. P1-304 Geldanamycin inhibits but does not reverse alpha-synuclein aggregation Neurobiology of Aging. 25: S183. DOI: 10.1016/S0197-4580(04)80617-1  0.641
2003 Klucken J, McLean PJ, Gomez-Tortosa E, Ingelsson M, Hyman BT. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochemical Research. 28: 1683-91. PMID 14584822 DOI: 10.1023/A:1026061021946  0.606
2002 McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. Journal of Neurochemistry. 83: 846-54. PMID 12421356 DOI: 10.1046/J.1471-4159.2002.01190.X  0.807
2002 McLean PJ, Hyman BT. An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neuroscience Letters. 323: 219-23. PMID 11959424 DOI: 10.1016/S0304-3940(02)00154-4  0.663
2001 Sharma N, McLean PJ, Kawamata H, Irizarry MC, Hyman BT. Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. Acta Neuropathologica. 102: 329-34. PMID 11603807 DOI: 10.1007/S004010100369  0.814
2001 McLean PJ, Kawamata H, Hyman BT. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 104: 901-12. PMID 11440819 DOI: 10.1016/S0306-4522(01)00113-0  0.828
2001 Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. The American Journal of Pathology. 159: 339-44. PMID 11438481 DOI: 10.1016/S0002-9440(10)61700-2  0.665
2001 Kawamata H, McLean PJ, Sharma N, Hyman BT. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. Journal of Neurochemistry. 77: 929-34. PMID 11331421 DOI: 10.1046/J.1471-4159.2001.00301.X  0.817
2000 Berezovska O, Jack C, McLean P, Aster JC, Hicks C, Xia W, Wolfe MS, Weinmaster G, Selkoe DJ, Hyman BT. Rapid Notch1 nuclear translocation after ligand binding depends on presenilin-associated gamma-secretase activity. Annals of the New York Academy of Sciences. 920: 223-6. PMID 11193154 DOI: 10.1111/J.1749-6632.2000.Tb06926.X  0.557
2000 McLean PJ, Ribich S, Hyman BT. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. Journal of Neural Transmission. Supplementum. 53-63. PMID 11128613 DOI: 10.1007/978-3-7091-6284-2_5  0.696
2000 Berezovska O, Jack C, McLean P, Aster JC, Hicks C, Xia W, Wolfe MS, Kimberly WT, Weinmaster G, Selkoe DJ, Hyman BT. Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. Journal of Neurochemistry. 75: 583-93. PMID 10899933 DOI: 10.1046/J.1471-4159.2000.0750583.X  0.574
2000 McLean PJ, Shpektor D, Bandyopadhyay S, Russek SJ, Farb DH. A minimal promoter for the GABA(A) receptor alpha6-subunit gene controls tissue specificity. Journal of Neurochemistry. 74: 1858-69. PMID 10800928 DOI: 10.1046/J.1471-4159.2000.0741858.X  0.728
2000 McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. The Journal of Biological Chemistry. 275: 8812-6. PMID 10722726 DOI: 10.1074/Jbc.275.12.8812  0.818
1999 Berezovska O, McLean P, Knowles R, Frosh M, Lu FM, Lux SE, Hyman BT. Notch1 inhibits neurite outgrowth in postmitotic primary neurons. Neuroscience. 93: 433-439. PMID 10465425 DOI: 10.1016/S0306-4522(99)00157-8  0.563
1999 Berezovska O, Frosch M, McLean P, Knowles R, Koo E, Kang D, Shen J, Lu FM, Lux SE, Tonegawa S, Hyman BT. The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons. Brain Research. Molecular Brain Research. 69: 273-80. PMID 10366748 DOI: 10.1016/S0169-328X(99)00119-9  0.571
1995 McLean PJ, Farb DH, Russek SJ. Mapping of the alpha 4 subunit gene (GABRA4) to human chromosome 4 defines an alpha 2-alpha 4-beta 1-gamma 1 gene cluster: further evidence that modern GABAA receptor gene clusters are derived from an ancestral cluster. Genomics. 26: 580-6. PMID 7607683 DOI: 10.1016/0888-7543(95)80178-O  0.723
Show low-probability matches.